QR code

HR+/HER2– de novo metastatic breast cancer: a true peculiar entity?

De novo metastatic breast cancer (dnMBC) accounts for ~6–10% of all breast cancers and for ~30% of MBC with increasing incidence over time. Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) tumours are the most frequent subtype with a similar incidence to that o...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: Rosalba Torrisi, Flavia Jacobs, Chiara Miggiano, Rita De Sanctis, Armando Santoro
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BioExcel Publishing Ltd 2023-03-01
Reeks:Drugs in Context
Onderwerpen:
hr+/her2– de novo metastatic breast cancer
locoregional treatment
stage iv breast cancer
systemic therapy
Online toegang:https://www.drugsincontext.com/hr-her2-de-novo-metastatic-breast-cancer-a-true-peculiar-entity/
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items